Skip to main content
Top
Published in: Tumor Biology 4/2016

01-04-2016 | Original Article

BAG3 regulates cell proliferation, migration, and invasion in human colorectal cancer

Authors: Huiyong Shi, Haidong Xu, Zengjun Li, Yanan Zhen, Bin Wang, Shoujun Huo, Ruixue Xiao, Zhongfa Xu

Published in: Tumor Biology | Issue 4/2016

Login to get access

Abstract

Bcl2-associated athanogene 3 (BAG3) has been reported to be elevated in various tumors. However, it is unclear whether BAG3 has a functional role in the initiation and progression of colorectal cancer (CRC). Here, we collected CRC samples and cell lines to validate the pathway by using gene and protein assays. RT-PCR showed that the expression of BAG3 mRNA in CRC tissues was obviously higher than that in non-tumor tissues (p < 0.001). Immunohistochemical analysis showed that immunoreactivity of BAG3 was found in most CRC tissues and strongly correlated with TNM stage (p = 0.001), differentiation (p = 0.003), and metastasis (p = 0.010). Low expression of BAG3 in HCT-8 significantly reduced cellular proliferation, migration, and invasion. The analysis of in vitro cell showed that HCT-8 cells were exposed to si-BAG3, and its growth was inhibited depending on modulation of cell cycle G1/S checkpoints and cell cycle regulators, involving cyclin D1, cyclin A2, and cyclin B1. Furthermore, suppression of the epithelial-mesenchymal transition (EMT) by si-BAG3 is linked to the decreased expression of E-cadherin and the increased expression of N-cadherin, vimentin, and MMP9. In conclusion, in the present study, we demonstrated that BAG3 overexpression plays a critical role in cell proliferation, migration, and invasion of colorectal cancer. Our data suggests targeted inhibition of BAG3 may be useful for patients with CRC.
Literature
1.
2.
3.
go back to reference Mano MS, Duhoux F. Colon cancer: update on adjuvant therapy. Clin Colorectal Cancer. 2008;7:178–83.CrossRefPubMed Mano MS, Duhoux F. Colon cancer: update on adjuvant therapy. Clin Colorectal Cancer. 2008;7:178–83.CrossRefPubMed
4.
go back to reference Gallagher DJ, Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology. 2010;78:237–48.CrossRefPubMed Gallagher DJ, Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology. 2010;78:237–48.CrossRefPubMed
6.
go back to reference Boo YJ, Park JM, Kim J, et al. L1 expression as a marker for poor prognosis, tumour progression, and short survival in patients with colorectal cancer. Ann Surg Oncol. 2007;14:1703–11.CrossRefPubMed Boo YJ, Park JM, Kim J, et al. L1 expression as a marker for poor prognosis, tumour progression, and short survival in patients with colorectal cancer. Ann Surg Oncol. 2007;14:1703–11.CrossRefPubMed
7.
go back to reference Shi P, Fang C, Pang X. Astrocyte elevated gene-1 regulates CCL3/CCR5-induced epithelial-to-mesenchymal transition via Erk1/2 and Akt signaling in cardiac myxoma. Oncol Rep. 2015;34(3):1319–26.PubMed Shi P, Fang C, Pang X. Astrocyte elevated gene-1 regulates CCL3/CCR5-induced epithelial-to-mesenchymal transition via Erk1/2 and Akt signaling in cardiac myxoma. Oncol Rep. 2015;34(3):1319–26.PubMed
8.
go back to reference Fuchs M, Poirier DJ, Seguin SJ, et al. Identification of the key structural motifs involved in HspB8/HspB6-Bag3 interaction. Biochem J. 2009;425(1):245–55.CrossRefPubMed Fuchs M, Poirier DJ, Seguin SJ, et al. Identification of the key structural motifs involved in HspB8/HspB6-Bag3 interaction. Biochem J. 2009;425(1):245–55.CrossRefPubMed
10.
go back to reference Zhu H, Wu W, Fu Y, et al. Overexpressed BAG3 is a potential therapeutic target in chronic lymphocytic leukemia. Ann Hematol. 2014;93(3):425–35.CrossRefPubMed Zhu H, Wu W, Fu Y, et al. Overexpressed BAG3 is a potential therapeutic target in chronic lymphocytic leukemia. Ann Hematol. 2014;93(3):425–35.CrossRefPubMed
11.
go back to reference Festa M, Del Valle L, Khalili K, et al. BAG3 protein is overexpressed in human glioblastoma and is a potential target for therapy. Am J Pathol. 2011;178(6):2504–12.CrossRefPubMedPubMedCentral Festa M, Del Valle L, Khalili K, et al. BAG3 protein is overexpressed in human glioblastoma and is a potential target for therapy. Am J Pathol. 2011;178(6):2504–12.CrossRefPubMedPubMedCentral
12.
go back to reference Gentilella A, Khalili K. BAG3 expression in glioblastoma cells promotes accumulation of ubiquitinated clients in an Hsp70-dependent manner. J Biol Chem. 2011;286(11):9205–15.CrossRefPubMedPubMedCentral Gentilella A, Khalili K. BAG3 expression in glioblastoma cells promotes accumulation of ubiquitinated clients in an Hsp70-dependent manner. J Biol Chem. 2011;286(11):9205–15.CrossRefPubMedPubMedCentral
13.
go back to reference Han G, Wu D, Yang Y, et al. CrkL meditates CCL20/CCR6-induced EMT in gastric cancer. Cytokine. 2015;76(2):163–9.CrossRefPubMed Han G, Wu D, Yang Y, et al. CrkL meditates CCL20/CCR6-induced EMT in gastric cancer. Cytokine. 2015;76(2):163–9.CrossRefPubMed
14.
go back to reference Lv B, Yang X, Lv S, et al. CXCR4 signaling induced epithelial-mesenchymal transition by PI3K/AKT and ERK pathways in glioblastoma. Mol Neurobiol. 2015;52(3):1263–8.CrossRefPubMed Lv B, Yang X, Lv S, et al. CXCR4 signaling induced epithelial-mesenchymal transition by PI3K/AKT and ERK pathways in glioblastoma. Mol Neurobiol. 2015;52(3):1263–8.CrossRefPubMed
15.
go back to reference Liao A, Wang W, Sun D, et al. Bone morphogenetic protein 2 mediates epithelial-mesenchymal transition via AKT and ERK signaling pathways in gastric cancer. Tumour Biol. 2015;36(4):2773–8.CrossRefPubMed Liao A, Wang W, Sun D, et al. Bone morphogenetic protein 2 mediates epithelial-mesenchymal transition via AKT and ERK signaling pathways in gastric cancer. Tumour Biol. 2015;36(4):2773–8.CrossRefPubMed
16.
go back to reference Niu H, Yang X, Xu Z, et al. Cell surface nucleolin interacts with CXCR4 receptor via the 212 c-terminal portion. Tumour Biol. 2015;36(2):1099–104.CrossRefPubMed Niu H, Yang X, Xu Z, et al. Cell surface nucleolin interacts with CXCR4 receptor via the 212 c-terminal portion. Tumour Biol. 2015;36(2):1099–104.CrossRefPubMed
17.
go back to reference Yang X, Lv S, Zhou X, et al. The clinical implications of transforming growth factor beta in pathological grade and prognosis of glioma patients: a meta-analysis. Mol Neurobiol. 2015;52(1):270–6.CrossRefPubMed Yang X, Lv S, Zhou X, et al. The clinical implications of transforming growth factor beta in pathological grade and prognosis of glioma patients: a meta-analysis. Mol Neurobiol. 2015;52(1):270–6.CrossRefPubMed
18.
go back to reference Pan Y, Zhang Y, Chen L, et al. The critical role of Rab31 in cell proliferation and apoptosis in cancer progression. Mol Neurobiol. 2015. Pan Y, Zhang Y, Chen L, et al. The critical role of Rab31 in cell proliferation and apoptosis in cancer progression. Mol Neurobiol. 2015.
19.
go back to reference Li J, Li H, Liu J, et al. The clinical implications of human telomerase reverse transcriptase expression in grade and prognosis of gliomas: a systematic review and meta-analysis. Mol Neurobiol. 2015. Li J, Li H, Liu J, et al. The clinical implications of human telomerase reverse transcriptase expression in grade and prognosis of gliomas: a systematic review and meta-analysis. Mol Neurobiol. 2015.
20.
go back to reference Ren G, Sheng L, Liu H, et al. The crucial role of SRPK1 in TGF-β-induced proliferation and apoptosis in the esophageal squamous cell carcinomas. Med Oncol. 2015;32(7):209.CrossRefPubMed Ren G, Sheng L, Liu H, et al. The crucial role of SRPK1 in TGF-β-induced proliferation and apoptosis in the esophageal squamous cell carcinomas. Med Oncol. 2015;32(7):209.CrossRefPubMed
Metadata
Title
BAG3 regulates cell proliferation, migration, and invasion in human colorectal cancer
Authors
Huiyong Shi
Haidong Xu
Zengjun Li
Yanan Zhen
Bin Wang
Shoujun Huo
Ruixue Xiao
Zhongfa Xu
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4403-1

Other articles of this Issue 4/2016

Tumor Biology 4/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine